ClinicalTrials.gg
Status unknownNCT02360709Updated Mar 25, 2015

Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions

An observational study in Coronary Artery Disease, sponsored by CID S.p.A.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-03-25.

Sponsored by CID S.p.A. · Observational

How we know

The sponsor has not verified this record recently (last verified Mar 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Planned enrollment
108th of 218
800 · median 720
Started
2014
with 13 others
Observational
219 of 543
82 open now
Registered
106th of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 108th largest by planned enrollment of the 218 observational ones that give a count, is one of 14 that started in 2014, is one of 219 observational ones, and was the 106th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy and deliverability of the CRE8 sirolimus-eluting stent system in the treatment of patients with de novo coronary artery lesions.

Read the detailed description

This is a prospective, multi-center, single-arm observational registry trial planned to enroll 800 subjects. All 800 subjects enrolled will receive CRE8 stents. Clinical follow-up will be performed at 1 month, 6 months,12 months and annually up to 5 years after the procedure.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This trial plans to enroll 800 subjects with de novo coronary artery lesions. Patients with reference diameter between 2.25mm and 4.5 mm (by visual estimation) and lesion length not more than 60mm (by visual estimation) will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and ≤ 75 years, male or female without pregnancy;
  • Patients with clinical evidence of asymptomatic heart disease, stable or unstable angina, or old myocardial infarction;
  • De novo lesions of native coronary arteries;
  • Target vessel diameter between 2.25mm and 4.5 mm, and target lesion length ≤ 60mm by visual estimation;
  • Target lesion diameter stenosis ≥ 70% by visual estimation;
  • Each target lesion must be implanted the same stent (CRE8);
  • Patients is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG);
  • Patients with ≥40%;
  • Patients who can understand the nature of the study, agree to participate and accept angiographic and clinical follow-up, and have provided written informed consents.

Exclusion criteria

Exclusion Criteria:

  • Patients with acute myocardial infarction (AMI) within 72 hours;
  • Chronic total occlusion lesion (TIMI flow 0 before procedure), Left main disease and/or triple-vessel lesion that might require treatment;
  • Heavily calcified or tortuous lesions which cannot be successfully pre-dilated, and lesions which are not suitable for stent delivery and deployment;
  • In-stent restenosis;
  • Thrombotic lesions;
  • Patients who had received any other stent in the past one year;
  • Patients with acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl);
  • Patients with cardiogenic shock, acute infection, known bleeding or coagulation disorder, or with a history of active gastrointestinal bleeding, ulcer, cerebral hemorrhage or subarachnoid hemorrhage and stroke within 6 months;
  • Patients who allergic to aspirin, clopidogrel, ticagrelor, ticlopidine, heparin, contrast agent, sirolimus, polymer, Co-Cr alloy, or with to aspirin or clopidogrel or ticagrelor;
  • Patients with less than 1year;
  • Patients who had participated in another drug or device trial that has not completed the primary endpoint;
  • Patient is in the opinion of the investigator, unable to comply with the requirements of the study protocol;
  • Patients who had underwent heart transplant surgery.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • CRE8 group

    CRE8 sirolimus-eluting stent

    Device: CRE8 sirolimus-eluting stent

Interventions

  • DeviceCRE8 sirolimus-eluting stent

    The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.

06

What researchers measure

Primary outcomes

  1. Target lesion failure (TLF,device-oriented endpoint)

    Time frame: 12months after the procedure

Secondary outcomes

  1. Target lesion failure (TLF,device-oriented endpoint)

    Time frame: 1month,6months,2years,3years,4years and 5years follow-up

  2. The patient-oriented composite endpoint includes all-cause death, all MIs, or any revascularizations

    Time frame: 1month,6months,12months and annually up to 5years follow-up

  3. Stent thrombosis per ARC definition

    Time frame: 1month,6months,12months and annually up to 5years follow-up

  4. device and lesion success rates

    Time frame: immidiately after the procedure

  5. clinical success rate

    Time frame: 7 days after the procedure

07

Study locations

1 of 1 sites recruiting
  • Fuwai Hospital,National Center for Cardiovasular disease
    Beijing, Beijing 100044, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Jan 2017 and a completion of Apr 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2015
First posted
Feb 11, 2015
Start
Nov 2014
Primary completionEst.
Jan 2017
CompletionEst.
Apr 2021
Last update
Mar 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02360709
Lead sponsor
CID S.p.A.
Responsible party
Sponsor
First posted
Feb 11, 2015
Start date
Nov 2014
Primary completion
Jan 2017 (estimated)
Completion
Apr 2021 (estimated)
Last update
Mar 25, 2015

Study contacts

Shubin Qiao, MD
Contact
qli@ccrfmed.com;qsbfw@sina.com
+86 13701237893
Shubin Qiao, MD
principal investigator · Fu Wai Hospital, National Center for Cardiovasular disease

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion